Denali Therapeutics Inc.
COMPOUND, COMPOSITIONS, AND METHODS

Last updated:

Abstract:

Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Status:
Application
Type:

Utility

Filling date:

29 Dec 2021

Issue date:

21 Apr 2022